News

David Weber, MD, MPH, explains what portion of the population may buy into the newly approved Pfizer-BioNTech vaccine.

Kevin J. Downes, MD, and Contagion® Section Editor Conan MacDougall, PharmD, MAS, BCPS, BCIDP, discuss these important topics as another season approaches.

With the full FDA approval of the Pfizer-BioNTech COVID-19 vaccine, Mark McClellan, MD, PhD, says more employer mandates will likely be coming, but he does not see federal government intervention in this area.

The most common adverse event was myocarditis, which was reported in nearly 500 patients. None of those patients had died as of the new analysis, and the rate per million cases was 3.5 cases.

The full approval for BNT162b2 will afford physicians greater prescribing capability, and will likely drive workplace vaccine mandates.

Findings increasingly suggest the mortality risk may be reduced by initiating daptomycin within 3 days of infection.

What does this form of pre-exposure prophylaxis (PrEP) mean in terms of options and initiation.

The decision on the final federal approval in the US could mean many more people would get the vaccine.

The World Health Organization (WHO) announces the Solidarity PLUS platform trial of drugs repurposed to treat COVID-19 after Solidarity trial candidates disappoint.

One of the major risk factors was a lack of follow-up healthcare services.

IgG titers were positively linked with symptom severity and certain comorbidities.

The US federal government announces plans for mRNA COVID-19 vaccine booster doses, and more children and teens are getting hospitalized for the virus.

The evolution of the major variants, including the delta mutation.

HIV risk perception and concern regarding HIV infection declined during the study.

Common cloth and surgical masks allow for the build-up of aerosol droplets over time.

A review of selected investigational long-active treatment options for HIV.

Infection preventionists at UCLA used active surveillance screening and technology to take a proactive approach to staving off any potential outbreaks of the emerging fungal infection in their health system.

While an association was found, the adverse events are very rare.

Long acting injectable PrEP therapies that are safe and effective are needed to increase options for at-risk individuals.

All Americans who received either Pfizer or Moderna will be eligible 8 months after their second dose.

Macro and micro strategies are at play in aiming to create greater PrEP access and adoption.

PrEP initiations, discontinuations and lapses all increased among Latinx patients post shelter-in-place orders.

The federal agency identified 3 more illnesses and the shrimp supplier expanded their recall.

The Biden administration reportedly hopes for FDA-authorized booster doses for the adult general population in the next month.

While the COVID-19 pandemic has helped advance respiratory diagnostics and surveillance, there are still many gaps that remain across the spectrum of healthcare.

The interconnectedness of many healthcare facilities such as nursing homes, hospitals, and long-term acute-care hospitals means a significant chance of multidrug-resistant organism transmission when patients shuttle between facilities.